BACKGROUND: The immunomodulatory nutritional product NR100157 was developed for human immunodeficiency virus (HIV)-infected individuals. We hypothesized that targeting the compromised gastrointestinal tract of HIV-infected individuals would result in systemic immunological benefits. METHODS: In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on antiretroviral therapy, with CD4(+) T-cell counts <800/µL, were given either NR100157 or an isocaloric and isonitrogenous control for 52 weeks. Primary outcome was CD4(+) T-cell count. Secondary outcomes included plasma viral load (pVL), safety, and tolerability. In a pilot study (n = 20), levels of CD4(+)CD25(+) and CD8(+)CD38(+) activation were measured (n = 20). The trial is registered at the Dutch Trial Register (NTR886) and ISRCTN81868024. RESULTS: At 52 weeks, CD4(+) T-cell decline showed a 40-cell/µL difference (P = .03) in the intention-to-treat population in favor of the immunomodulatory NR100157 (control vs active, -68 ± 15 vs -28 ± 16 cells/µL/year). The change in pVL from baseline was similar between groups (P = .81). In the pilot study, the percentage of CD4(+)CD25(+) was lower in the active group (P < .05) and correlated with changes in CD4(+) T-cell count (r = -0.55, P < .05). The percentage of CD8(+)CD38(+) levels was unaffected. CONCLUSIONS: The specific immunonutritional product NR100157 significantly reduces CD4(+) decline in HIV-1-infected individuals, and this is associated with decreased levels of CD4(+)CD25(+). (This nutritional intervention is likely to affect local gut integrity and gut-associated lymphoid tissue homeostasis, which in turn translates positively to systemic effects.) Clinical Trials Registration. ISRCTN81868024.
RCT Entities:
BACKGROUND: The immunomodulatory nutritional product NR100157 was developed for human immunodeficiency virus (HIV)-infected individuals. We hypothesized that targeting the compromised gastrointestinal tract of HIV-infected individuals would result in systemic immunological benefits. METHODS: In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on antiretroviral therapy, with CD4(+) T-cell counts <800/µL, were given either NR100157 or an isocaloric and isonitrogenous control for 52 weeks. Primary outcome was CD4(+) T-cell count. Secondary outcomes included plasma viral load (pVL), safety, and tolerability. In a pilot study (n = 20), levels of CD4(+)CD25(+) and CD8(+)CD38(+) activation were measured (n = 20). The trial is registered at the Dutch Trial Register (NTR886) and ISRCTN81868024. RESULTS: At 52 weeks, CD4(+) T-cell decline showed a 40-cell/µL difference (P = .03) in the intention-to-treat population in favor of the immunomodulatory NR100157 (control vs active, -68 ± 15 vs -28 ± 16 cells/µL/year). The change in pVL from baseline was similar between groups (P = .81). In the pilot study, the percentage of CD4(+)CD25(+) was lower in the active group (P < .05) and correlated with changes in CD4(+) T-cell count (r = -0.55, P < .05). The percentage of CD8(+)CD38(+) levels was unaffected. CONCLUSIONS: The specific immunonutritional product NR100157 significantly reduces CD4(+) decline in HIV-1-infected individuals, and this is associated with decreased levels of CD4(+)CD25(+). (This nutritional intervention is likely to affect local gut integrity and gut-associated lymphoid tissue homeostasis, which in turn translates positively to systemic effects.) Clinical Trials Registration. ISRCTN81868024.
Authors: S Serrano-Villar; J F Vázquez-Castellanos; A Vallejo; A Latorre; T Sainz; S Ferrando-Martínez; D Rojo; J Martínez-Botas; J Del Romero; N Madrid; M Leal; J I Mosele; M J Motilva; C Barbas; M Ferrer; A Moya; S Moreno; M J Gosalbes; V Estrada Journal: Mucosal Immunol Date: 2016-12-21 Impact factor: 7.313
Authors: A Calcagno; S Nozza; C Muss; B M Celesia; F Carli; S Piconi; G V De Socio; A M Cattelan; G Orofino; D Ripamonti; A Riva; G Di Perri Journal: Infection Date: 2015-05-19 Impact factor: 3.553
Authors: María José Gosalbes; Nuria Jimenéz-Hernandéz; Elena Moreno; Alejandro Artacho; Xavier Pons; Sonia Ruíz-Pérez; Beatriz Navia; Vicente Estrada; Mónica Manzano; Alba Talavera-Rodriguez; Nadia Madrid; Alejandro Vallejo; Laura Luna; José A Pérez-Molina; Santiago Moreno; Sergio Serrano-Villar Journal: Gut Microbes Date: 2022 Jan-Dec
Authors: Allan R Tenorio; Ellen S Chan; Ronald J Bosch; Bernard J C Macatangay; Sarah W Read; Suria Yesmin; Babafemi Taiwo; David M Margolis; Jeffrey M Jacobson; Alan L Landay; Cara C Wilson Journal: J Infect Dis Date: 2014-09-11 Impact factor: 5.226
Authors: David B Allison; Josep Bassaganya-Riera; Barbara Burlingame; Andrew W Brown; Johannes le Coutre; Suzanne L Dickson; Willem van Eden; Johan Garssen; Raquel Hontecillas; Chor San H Khoo; Dietrich Knorr; Martin Kussmann; Pierre J Magistretti; Tapan Mehta; Adrian Meule; Michael Rychlik; Claus Vögele Journal: Front Nutr Date: 2015-09-08